{"id":"NCT01452919","sponsor":"Denovo Biopharma LLC","briefTitle":"A Physical Dependence Study in Schizophrenia","officialTitle":"A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-10-17","resultsPosted":"2021-09-16","lastUpdate":"2022-09-14"},"enrollment":123,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"LY2140023","otherNames":["pomaglumetad methionil"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"LY2140023/LY2140023","type":"EXPERIMENTAL"},{"label":"LY2140023/Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using it.\n\nThis trial consists of two phases: An open-label phase consisting of up to 4 weeks and a double-blind phase consisting of up to 3 weeks.","primaryOutcome":{"measure":"Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score","timeFrame":"Randomization up to Week 2 of randomization treatment","effectByArm":[{"arm":"Placebo (Randomization)","deltaMin":13.23,"sd":0.96},{"arm":"LY2140023 (Randomization)","deltaMin":11.5,"sd":0.99}],"pValues":[{"comp":"OG000 vs OG001","p":"0.170"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":10,"countries":["United States","Greece"]},"refs":{"pmids":["25006819"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":123},"commonTop":["Nausea","Headache","Anxiety","Tremor","Agitation"]}}